Presentation is loading. Please wait.

Presentation is loading. Please wait.

Renal Sympathetic Denervation: The Academic View

Similar presentations


Presentation on theme: "Renal Sympathetic Denervation: The Academic View"— Presentation transcript:

1 Renal Sympathetic Denervation: The Academic View
Krishna Rocha-Singh, M.D., FACC, FSVM, FSCAI Associate Clinical Professor of Medicine SIU School of Medicine Springfield, IL

2 Krishna Rocha-Singh, M.D.
Research None Consultant/Advisory Board/Training Medtronic ev3, Inc. Minnow Ardian (expired) Royalties/Financial Interest None VIVA Board Member salary Medical Director PERC, salary I will discuss a vascular device which is unavailable in the US

3 Ardian Renal Denervation:
A Case Study in ‘Bench to Bedside’ The ‘mechanism of action’ of the Ardian device been defined in pre-clinical animal models Important ‘denervation surrogates’ have been defined (NE tissue levels, ‘NE spillover’, MSNA…) The pre-clinical safety of the ‘mechanism of action’ established

4 Anatomy of Renal Sympathetic Nerves
Vessel Lumen Approx. 70% of renal nerves are within 1.5mm of the ostium of the human renal artery The 95% of renal nerves are within 2.5mm of the vessel lumen Media Adventitia Renal Nerves Atherton 2011 4 4

5 1st Generation Symplicity™ Catheter
Used in Symplicity I and II Trials

6 2nd Generation Symplicity™ Catheter
Symplicity® Catheter System, Ardian, Inc., Palo Alto, CA, USA 6F compatible Articulating tip Designed for renal artery use Used in US pilot trial In the United States: Caution: Investigational Device. Limited by U.S. law to investigational use. 6

7 Pre-clinical Animal Work
Safety: Swine model with angiography, gross pathology, histopathology & clinical pathology at 7, 30, 60 & 180 days Intact endothelium by 7 days Vascular healing observed at 30 days, complete in some by 60 days No renal artery stenosis out to 180 days Effectiveness: Cath lab procedure is comparable to surgical denervation Renal Tissue Norepinephrine (pg/mg)

8 Symplicity HTN I: FIM Study Aims:
First-in-man 12-month evaluation of the safety and blood pressure-lowering efficacy of percutaneous renal sympathetic denervation in patients with refractory hypertension Study Sites: Melbourne & Newcastle, Australia; Krakow, Poland; & Frankfurt, Germany Krum et al. Lancet. 2009;373(9671): 8 8

9 Symplicity 2- HTN Trial Design:
‘Defining the Appropriate Patient’ Baseline Drop-Outs Registry Treatment Group Control Patients offered treatment Suboptimal Anatomy Control Group Primary Endpoint 6M 12-36M Anatomical Screening (MRA, CTA, duplex or angiogram) 24-hr ABPM Randomized 1:1 Uncontrolled HTN SBP ≥ 160 mmHg (≥ 150 mmHg diabetics) ≥ 3 meds “Baseline” 2 week observation Baseline BP measure at end of baseline period ClinicalTrials.gov Identifier: NCT 9

10 Defining the ‘Appropriate Patient’: Symplicity-2 Trial Patient Disposition
Assessed for Eligibility (n=190) Excluded Prior to Randomization (n=84) BP <160 after 2-weeks of compliance confirmation (n=36; 19%) Ineligible anatomy (n=30; 16%) Declined participation (n=10; 5%) Other exclusion criteria discovered after consent (n=8; 4%) Randomized (n=106) Allocated to RDN (n=52) Allocated to Control (n = 54) No Six-Month Primary Endpoint Visit (n = 3) Reasons: Withdrew consent (n=1) Missed visit (n=2) Withdrew consent (n=2) Lost to follow-up (n=1) Analyzed (n = 49) Analyzed (n = 51) Symplicity HTN-2 Investigators. The Lancet 2010: 376: . 10

11 Renal Sympathetic Denervation: This is a BIG Deal…
Moreover… Important ‘collateral’ beneficial biological effects of RDN are emerging: Effect on glucose sensitivity Obstructive sleep apnea? Cardio-renal Syndromes? The substantial reduction of SBP, an established and accepted surrogate, cannot be under-emphasized

12 Renal Denervation: ‘Collateral’ Benefits
0 min 60 min 120 min Glucose concentration (mg/dl) 3 months (n=15) * *significant reduction (p<0.05) compared to baseline 270 6 months (n=7) Baseline (n=25) 250 230 210 180 150 120 90 Oral Glucose Tolerance Test (75 g) RDN is associated with improved glucose control in diabetic patients with resistant HTN Mahfoud et al. Deutche Gesellschaft Für Kardiologie: Jahrestagung Mannheim.  April 2010.

13 Can Renal Denervation Improve Glucose Metabolism?
Timepoint Fasting Glucose (mg/dl) Insulin (mU/l) C-peptide (µg/l) HOMA-IR Baseline (n=25) 118 ± 20 22.3 ± 14.8 6.2 ± 3.6 6.2 ± 4.3 1 month (n=21) 113 ± 14 10.9 ± 7.3* 3.2 ± 1.5* 3.0 ± 1.8* 3 months (n=15) 102 ± 12* 8.4 ± 4.8* 3.0 ± 1.1* 2.1 ± 1.3* 6 months (n=7) 99 ± 18* 8.8 ± 4.6 3.1 ± 1.1 2.2 ± 1.4 *significant reduction (p<0.05) compared to baseline Mahfoud et al. Deutche Gesellschaft Für Kardiologie: Jahrestagung Mannheim.  April 2010. 13

14 Renal Denervation: Questions to be Answered
What is the clinical ‘durability’ RDN? Will ‘next gen’ catheter designs address its anatomical limitations? How do we explain the ‘non-responders? Can its clinical indications be expanded beyond HTN? 14 14

15 Ardian Has Set a High Bar… for the Competition
FIM and RCT trials have established ‘proof-of-concept’, safety and effectiveness in patients with resistant HTN Many issues will be debated, but the potential for tremendous clinical impact is undeniable The Symplicity HTN 3 cohort size (?) will be driven by safety issues…not by treatment effect…so how do we get this important innovation ‘on-label’ expeditiously?


Download ppt "Renal Sympathetic Denervation: The Academic View"

Similar presentations


Ads by Google